Pembrolizumab vs Tislelizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Pembrolizumab
Marketed by Merck & Co.
NCT02142738 · Phase 3 · completed
The trial randomized 305 participants to pembrolizumab or active platinum-based chemotherapy, but treatment was open-label rather than double-blinded. Its radiographically assessed primary endpoint, 6-month progression-free survival, was met: 62.1% with pembrolizumab versus 50.3% with chemotherapy, with p<0.001 and a hazard ratio of 0.50 (95% CI 0.37–0.68).
Next expected readout: November 2026 · NCT06545331 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) Rate at Month 6: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2) (met)
Result source: NCT02142738
Tislelizumab
Marketed by BeOne Medicines and partners
NCT03358875 · Phase 3 · completed
The 805-participant trial was randomized and actively controlled with docetaxel, and its co-primary clinical endpoint of overall survival was met in both the full population and the PD-L1-positive subgroup. However, treatment assignment was not blinded, so despite the large sample and statistically significant survival results, the evidence is rated moderate rather than strong.
Next expected readout: November 2026 · NCT06704620 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Pembrolizumab | Tislelizumab |
|---|---|---|
| PFS, median | 8.8 vs 4.9+3.9 vs placeboNCT0257868017 other results
| 7.6 vs 5.5vs Paclitaxel + CarboplatinNCT035947475 other results
|
| OS, median | 15.9 vs 11.3+4.6 vs placeboNCT0277543515 other results
| 26.1 vs 19.4vs Paclitaxel + CarboplatinNCT035947471 other result
|
| ORR | 47.6% vs 18.9%+28.7 vs placeboNCT0257868014 other results
| 74.2% vs 47.9%vs Paclitaxel + CarboplatinNCT035947473 other results
|
| Duration of response, median | 11.2 vs 7.8+3.4 vs placeboNCT025786808 other results
| 8.4 vs 4.3vs Paclitaxel + CarboplatinNCT035947473 other results
|
PFS, median
- Pembrolizumab
- 8.8 vs 4.9+3.9 vs placeboNCT02578680
17 other results
- 6.4 vs 4.8 NCT02775435
- 5.6 vs 5.5 NCT03515837
- 5.6 vs 4.2 NCT03976375
- 4 vs 2.5 NCT02864394
- 3.3 vs 3 NCT02864394
- 7.1 NCT03976323
- 8.3 NCT03976323
- 6.5 vs 6.4 NCT02220894
- 6.2 vs 6.7 NCT02220894
- 5.4 vs 6.6 NCT02220894
- 2.5 vs 2.4 NCT04165096
- 4.5 vs 5.2 NCT03971474
- 29 NCT03631784
- 45.3 NCT03631784
- 7 NCT05077709
- 2.6 NCT02955758
- 4.4 NCT02733159
- Tislelizumab
- 7.6 vs 5.5vs Paclitaxel + CarboplatinNCT03594747
5 other results
- 7.6 vs 5.5 NCT03594747
- 7.7 vs 5.5 NCT03594747
- 9.6 vs 5.5 NCT03594747
- 9.6 vs 5.5 NCT03594747
- 9.8 vs 5.5 NCT03594747
OS, median
- Pembrolizumab
- 15.9 vs 11.3+4.6 vs placeboNCT02775435
15 other results
- 15.9 vs 14.7 NCT03515837
- 20 vs 12.2 NCT02220894
- 18 vs 13 NCT02220894
- 16.4 vs 12.1 NCT02220894
- 11.3 vs 12 NCT03976375
- 12.3 vs 10.9 NCT02864394
- 12.9 vs 10.6 NCT02864394
- 20.7 NCT03976323
- 23 NCT03976323
- 14.5 vs 11.6 NCT03971474
- 35.6 NCT03631784
- 56.7 NCT03631784
- 9.8 NCT02733159
- 22.3 NCT05077709
- 13.3 NCT02955758
- Tislelizumab
- 26.1 vs 19.4vs Paclitaxel + CarboplatinNCT03594747
1 other result
- 23.3 vs 19.4 NCT03594747
ORR
- Pembrolizumab
- 47.6% vs 18.9%+28.7 vs placeboNCT02578680
14 other results
- 57.9% vs 38.4% NCT02775435
- 29% vs 27.1% NCT03515837
- 39.1% vs 32% NCT02220894
- 33.2% vs 28.9% NCT02220894
- 27.2% vs 26.5% NCT02220894
- 44.8% vs 27.8% NCT02142738
- 22.7% vs 14.3% NCT03976375
- 22.7% vs 12.5% NCT03976375
- 28.1% vs 7.1% NCT02864394
- 20.7% vs 5.7% NCT02864394
- 5.4% vs 11.1% NCT04165096
- 71.4% NCT03631784
- 75.5% NCT03631784
- 22% vs 28% NCT03971474
- Tislelizumab
- 74.2% vs 47.9%vs Paclitaxel + CarboplatinNCT03594747
3 other results
- 73.9% vs 47.9% NCT03594747
- 70% vs 49.6% NCT03594747
- 78.2% vs 49.6% NCT03594747
Duration of response, median
- Pembrolizumab
- 11.2 vs 7.8+3.4 vs placeboNCT02578680
8 other results
- 7.7 vs 4.8 NCT02775435
- 6.3 vs 5.6 NCT03515837
- 6.9 vs 6.8 NCT03976375
- 16.6 vs 6.4 NCT02864394
- 16.6 vs 6.3 NCT02864394
- 12.9 vs 5.6 NCT03971474
- 14.6 NCT02733159
- 12.5 NCT05077709
- Tislelizumab
- 8.4 vs 4.3vs Paclitaxel + CarboplatinNCT03594747
3 other results
- 8.6 vs 4.3 NCT03594747
- 10.6 vs 4.8 NCT03594747
- 8.8 vs 4.8 NCT03594747
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Pembrolizumab: 5 of 5 rows · Tislelizumab: 3 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Pembrolizumab Rows use multiple source trials | Tislelizumab |
|---|---|---|
| EORTC QLQ-C30 GHS absolute change · score No placebo or comparator arm | -5.34 score @ 24wka,b,c NCT03976323 · Phase 3 · registry result, not featured evidence · combination show 1 more dose-3.44 score @ 24wk NCT03976323 · Phase 3 · registry result, not featured evidence · combination | 3.3 score @ 15wka,b,c NCT03594747 · Phase 3 · registry result, not featured evidence · combination show 1 more dose2.4 score @ 15wk NCT03594747 · Phase 3 · registry result, not featured evidence · combination |
| Dropout rate | n/a: no completion milestonePembrolizumabd NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 48 more results—Pembrolizumab First Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 —Pembrolizumab Second Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 54%10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 58.8%2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 n/a: no completion milestonePembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination —Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination n/a: no completion milestone NCT02775435 · Phase 3 · combination n/a: no completion milestone NCT02220894 · Phase 3 n/a: no completion milestone NCT02504372 · Phase 3 89.3%200 mg IV Q3W NCT03715205 · Phase 4 · registry result, not featured evidence —Pembrolizumab (First Course) + Ola NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (First Course) + Pem NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (Second Course) + Ol NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (Second Course) + Pe NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Olaparib (Maintena NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Pemetrexed (Mainte NCT03976323 · Phase 3 · registry result, not featured evidence · combination 33%Pembrolizumab + Pemetrexed + Plati NCT03976323 · Phase 3 · registry result, not featured evidence · combination 0%Arm 1 Stereotactic Body Radiation NCT03867175 · Phase 3 · registry result, not featured evidence · combination 0%Arm 2 Pembrolizumab Only NCT03867175 · Phase 3 · registry result, not featured evidence —Pembrolizumab + Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestonePembrolizumab+Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT03515837 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT03875092 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT03950674 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT02864394 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT03850444 · Phase 3 · registry result, not featured evidence 2.5% NCT03634241 · Phase 2 · registry result, not featured evidence 90.5%Arm B (SCCHN) NCT05077709 · Phase 2 · registry result, not featured evidence · combination 60%Arm C (mUBC) NCT05077709 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone800 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone200 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestonePembrolizumab + Lenvatinib NCT03516981 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestonePembrolizumab + Quavonlimab NCT03516981 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone NCT04165096 · Phase 2 · registry result, not featured evidence · combination 0%Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence 50%Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence 80.7%1st Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 89.2%2nd Line HNSCC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 94.4%2nd Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 0% NCT02955758 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePembrolizumab + cCRT + Paclitaxel NCT03631784 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestonePembrolizumab + cCRT + Pemetrexed NCT03631784 · Phase 2 · registry result, not featured evidence · combination 3.2% NCT02733159 · Phase 2 · registry result, not featured evidence 87.7% NCT03004183 · Phase 2 · registry result, not featured evidence n/a: no completion milestone NCT03971474 · Phase 2 · registry result, not featured evidence · combination 86.4% NCT03087760 · Phase 2 · registry result, not featured evidence | n/a: no completion milestoneTislelizumab + Nab-paclitaxel + Cae NCT03594747 · Phase 3 · registry result, not featured evidence · combination show 1 more resultn/a: no completion milestoneTislelizumab + Paclitaxel + Carbop NCT03594747 · Phase 3 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 8.4%Pembrolizumabd NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 48 more results—Pembrolizumab First Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 —Pembrolizumab Second Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 4.9%10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 6.7%2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination —Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination 11.5% NCT02775435 · Phase 3 · combination 19.9% NCT02220894 · Phase 3 — NCT02504372 · Phase 3 —200 mg IV Q3W NCT03715205 · Phase 4 · registry result, not featured evidence —Pembrolizumab (First Course) + Ola NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (First Course) + Pem NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (Second Course) + Ol NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (Second Course) + Pe NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Olaparib (Maintena NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Pemetrexed (Mainte NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Pemetrexed + Plati NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Arm 1 Stereotactic Body Radiation NCT03867175 · Phase 3 · registry result, not featured evidence · combination —Arm 2 Pembrolizumab Only NCT03867175 · Phase 3 · registry result, not featured evidence —Pembrolizumab + Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab+Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination — NCT03515837 · Phase 3 · registry result, not featured evidence · combination 3.1% NCT03875092 · Phase 3 · registry result, not featured evidence · combination — NCT03950674 · Phase 3 · registry result, not featured evidence · combination — NCT02864394 · Phase 3 · registry result, not featured evidence 12.5% NCT03850444 · Phase 3 · registry result, not featured evidence — NCT03634241 · Phase 2 · registry result, not featured evidence —Arm B (SCCHN) NCT05077709 · Phase 2 · registry result, not featured evidence · combination —Arm C (mUBC) NCT05077709 · Phase 2 · registry result, not featured evidence · combination —800 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination —200 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination —Pembrolizumab + Lenvatinib NCT03516981 · Phase 2 · registry result, not featured evidence · combination —Pembrolizumab + Quavonlimab NCT03516981 · Phase 2 · registry result, not featured evidence · combination — NCT04165096 · Phase 2 · registry result, not featured evidence · combination —Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence —Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence —1st Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination —2nd Line HNSCC NCT03625323 · Phase 2 · registry result, not featured evidence · combination —2nd Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination — NCT02955758 · Phase 2 · registry result, not featured evidence —Pembrolizumab + cCRT + Paclitaxel NCT03631784 · Phase 2 · registry result, not featured evidence · combination —Pembrolizumab + cCRT + Pemetrexed NCT03631784 · Phase 2 · registry result, not featured evidence · combination 1.6% NCT02733159 · Phase 2 · registry result, not featured evidence 12.3% NCT03004183 · Phase 2 · registry result, not featured evidence 11.6% NCT03971474 · Phase 2 · registry result, not featured evidence · combination — NCT03087760 · Phase 2 · registry result, not featured evidence | —Tislelizumab + Nab-paclitaxel + Cae NCT03594747 · Phase 3 · registry result, not featured evidence · combination show 1 more result—Tislelizumab + Paclitaxel + Carbop NCT03594747 · Phase 3 · registry result, not featured evidence · combination |
| Serious AEs | —Pembrolizumabd NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 48 more results51.3%Pembrolizumab First Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 16.7%Pembrolizumab Second Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 —10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 38.8%10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 36.6%2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 57.5%Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination 22.2%Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination 46% NCT02775435 · Phase 3 · combination 41% NCT02220894 · Phase 3 24.5% NCT02504372 · Phase 3 20.7%200 mg IV Q3W NCT03715205 · Phase 4 · registry result, not featured evidence 35%Pembrolizumab (First Course) + Ola NCT03976323 · Phase 3 · registry result, not featured evidence · combination 37.7%Pembrolizumab (First Course) + Pem NCT03976323 · Phase 3 · registry result, not featured evidence · combination 0%Pembrolizumab (Second Course) + Ol NCT03976323 · Phase 3 · registry result, not featured evidence · combination 7.7%Pembrolizumab (Second Course) + Pe NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Olaparib (Maintena NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Pemetrexed (Mainte NCT03976323 · Phase 3 · registry result, not featured evidence · combination 23.4%Pembrolizumab + Pemetrexed + Plati NCT03976323 · Phase 3 · registry result, not featured evidence · combination 50%Arm 1 Stereotactic Body Radiation NCT03867175 · Phase 3 · registry result, not featured evidence · combination 100%Arm 2 Pembrolizumab Only NCT03867175 · Phase 3 · registry result, not featured evidence 54.7%Pembrolizumab + Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab+Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination 35.1% NCT03515837 · Phase 3 · registry result, not featured evidence · combination 53.8% NCT03875092 · Phase 3 · registry result, not featured evidence · combination 36% NCT03950674 · Phase 3 · registry result, not featured evidence · combination 36.2% NCT02864394 · Phase 3 · registry result, not featured evidence 32.8% NCT03850444 · Phase 3 · registry result, not featured evidence 7.5% NCT03634241 · Phase 2 · registry result, not featured evidence 9.5%Arm B (SCCHN) NCT05077709 · Phase 2 · registry result, not featured evidence · combination 20%Arm C (mUBC) NCT05077709 · Phase 2 · registry result, not featured evidence · combination 60.8%800 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination 46.7%200 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination 52.5%Pembrolizumab + Lenvatinib NCT03516981 · Phase 2 · registry result, not featured evidence · combination 47.6%Pembrolizumab + Quavonlimab NCT03516981 · Phase 2 · registry result, not featured evidence · combination 37.8% NCT04165096 · Phase 2 · registry result, not featured evidence · combination 10.8%Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence 20%Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence 47.4%1st Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 54.1%2nd Line HNSCC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 25%2nd Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 36% NCT02955758 · Phase 2 · registry result, not featured evidence 58.9%Pembrolizumab + cCRT + Paclitaxel NCT03631784 · Phase 2 · registry result, not featured evidence · combination 45.1%Pembrolizumab + cCRT + Pemetrexed NCT03631784 · Phase 2 · registry result, not featured evidence · combination 85% NCT02733159 · Phase 2 · registry result, not featured evidence 51.8% NCT03004183 · Phase 2 · registry result, not featured evidence 40.6% NCT03971474 · Phase 2 · registry result, not featured evidence · combination 45.5% NCT03087760 · Phase 2 · registry result, not featured evidence | 46.6%Tislelizumab + Nab-paclitaxel + Cae NCT03594747 · Phase 3 · registry result, not featured evidence · combination show 1 more result46.7%Tislelizumab + Paclitaxel + Carbop NCT03594747 · Phase 3 · registry result, not featured evidence · combination |
| Most frequent reported AEs | d diarrhoea 26.6% dyspnoea 26.6% fatigue 24% NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 42 more resultsupper respiratory tract infection 33.3% constipation 16.7% decreased appetite 16.7% NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 10 mg/kg fatigue 25.7% decreased appetite 23.3% dyspnoea 23% NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 2 mg/kg decreased appetite 30.7% fatigue 30.1% nausea 25.7% NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 nausea 57.3% (placebo 51%) anaemia 45.9% (placebo 45%) fatigue 42.7% (placebo 39.6%) NCT02578680 · Phase 3 · combination abdominal pain 22.2% (placebo 6.4%) cough 22.2% (placebo 30.7%) diarrhoea 22.2% (placebo 20.3%) NCT02578680 · Phase 3 · combination anaemia 53.2% (placebo 49.6%) alopecia 46% (placebo 37.5%) nausea 36.3% (placebo 32.1%) NCT02775435 · Phase 3 · combination weight increased 22.8% (placebo 28.9%) pruritus 21.6% (placebo 12.7%) hypothyroidism 20.7% (placebo 4.6%) NCT02504372 · Phase 3 200 mg IV Q3W hypothyroidism 17.3% anaemia 12.7% constipation 11.3% NCT03715205 · Phase 4 · registry result, not featured evidence anaemia 36.2% nausea 24% fatigue 17.2% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anaemia 37.7% nausea 19% aspartate aminotransferase increased 16.6% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anaemia 14.3% covid-19 14.3% headache 14.3% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anaemia 15.4% cough 15.4% productive cough 15.4% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anaemia 38.4% nausea 30.9% neutropenia 23.4% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anemia 75% cough 75% abdominal pain 50% NCT03867175 · Phase 3 · registry result, not featured evidence · combination alanine aminotransferase increased 100% alkaline phosphatase increased 100% aspartate aminotransferase increased 100% NCT03867175 · Phase 3 · registry result, not featured evidence hypertension 41.4% diarrhoea 40.9% hypothyroidism 35.4% NCT03976375 · Phase 3 · registry result, not featured evidence · combination anaemia 40.4% (placebo 44.7%) nausea 39.2% (placebo 43.5%) neutrophil count decreased 36.7% (placebo 45.9%) NCT03515837 · Phase 3 · registry result, not featured evidence · combination alopecia 78.5% white blood cell count decreased 78.5% neutrophil count decreased 76.9% NCT03875092 · Phase 3 · registry result, not featured evidence · combination nausea 72% (placebo 53.3%) constipation 64% (placebo 73.3%) decreased appetite 56% (placebo 60%) NCT03950674 · Phase 3 · registry result, not featured evidence · combination anaemia 33.3% aspartate aminotransferase increased 21.6% cough 21.6% NCT02864394 · Phase 3 · registry result, not featured evidence fatigue 45% investigations 25% alanine aminotransferase increased 20% NCT03634241 · Phase 2 · registry result, not featured evidence anaemia 42.9% diarrhoea 33.3% fatigue 28.6% NCT05077709 · Phase 2 · registry result, not featured evidence · combination asthenia 40% blood creatinine increased 40% blood urea increased 40% NCT05077709 · Phase 2 · registry result, not featured evidence · combination 800 mg diarrhoea 29.4% fatigue 21.6% alanine aminotransferase increased 19.6% NCT03516981 · Phase 2 · registry result, not featured evidence · combination 200 mg pyrexia 23.3% constipation 20% decreased appetite 20% NCT03516981 · Phase 2 · registry result, not featured evidence · combination hypertension 52.5% diarrhoea 45% hypothyroidism 36.3% NCT03516981 · Phase 2 · registry result, not featured evidence · combination pruritus 29.3% cough 22% fatigue 20.7% NCT03516981 · Phase 2 · registry result, not featured evidence · combination fatigue 29.7% pruritus 29.7% nausea 24.3% NCT04165096 · Phase 2 · registry result, not featured evidence · combination anorexia 40% gastrointestinal disorders - other, specify 40% hypertension 40% NCT02681549 · Phase 2 · registry result, not featured evidence asthenia 34.2% dyspnoea 34.2% cough 29.8% NCT03625323 · Phase 2 · registry result, not featured evidence · combination asthenia 21.6% anaemia 18.9% cough 18.9% NCT03625323 · Phase 2 · registry result, not featured evidence · combination decreased appetite 36.1% dyspnoea 36.1% cough 30.6% NCT03625323 · Phase 2 · registry result, not featured evidence · combination nausea 24% decreased appetite 20% worsening abdominal pain 20% NCT02955758 · Phase 2 · registry result, not featured evidence anaemia 39.3% fatigue 34.8% alopecia 31.3% NCT03631784 · Phase 2 · registry result, not featured evidence · combination nausea 52% asthenia 40.2% anaemia 32.4% NCT03631784 · Phase 2 · registry result, not featured evidence · combination fatigue 21.4% nausea 12.5% back pain 10.7% NCT03004183 · Phase 2 · registry result, not featured evidence fatigue 56.5% hypoalbuminemia 44.9% hyponatremia 39.1% NCT03971474 · Phase 2 · registry result, not featured evidence · combination esophagitis 36.4% fatigue 36.4% hypothyroidism 22.7% NCT03087760 · Phase 2 · registry result, not featured evidence | e anaemia 94.1% alopecia 69.5% neutrophil count decreased 61.9% NCT03594747 · Phase 3 · registry result, not featured evidence · combination show 1 more resultanaemia 89.2% alopecia 65% neutrophil count decreased 65% NCT03594747 · Phase 3 · registry result, not featured evidence · combination |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cAssessment timepoints differ: 24 weeks versus 15 weeks.
- dPopulation comparability has not been reviewed for 42 of these studies.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Pembrolizumab
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 7 more results
show 8 more results
show 1 more result
show 3 more results
show 3 more results
+ 43 further endpoints in the CSV export.
Tislelizumab
show 1 more result
show 1 more result
Gastric Cancer
Shared mechanism: PD-1 · full Gastric Cancer pipeline
Pembrolizumab
Marketed by Merck & Co.
NCT03615326 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled phase 3 trial; 698 participants were randomized in its main cohort, more than the approximately 692 its published sample-size calculation required. Both primary endpoints were met: progression-free survival by blinded central review (hazard ratio 0.73) and overall survival (hazard ratio 0.80) were significantly better with pembrolizumab.
Next expected readout: December 2026 · NCT05041153 (registry estimate)
No aligned efficacy figure on record for this race.
Tislelizumab
Marketed by BeOne Medicines and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05238883 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Gastric Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Tislelizumab: registry results are on file for Gastric Cancer, but their comparison mappings are not yet available.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Pembrolizumab
show 11 more results
show 14 more results
show 15 more results
show 9 more results
show 5 more results
show 3 more results
show 3 more results
Available safety results
Pembrolizumab
| Dropout rate | n/a: no completion milestoneCohort A: Triple Negative Breast C NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 27 more resultsn/a: no completion milestoneCohort B: Ovarian Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort C: Gastric Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort D1: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort D2: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence n/a: no completion milestoneCohort E: Glioblastoma Multiforma NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort F: Biliary Tract Cancer (Le NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort G: Pancreatic Cancer (Lenva NCT03797326 · Phase 2 · registry result, not featured evidence · combination 25%Experimental: Expansion 1 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 0%Experimental: Expansion 2 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 4.8%Experimental: Expansion 3 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 0%Experimental: Safety Lead In NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1.6 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1.6 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination |
|---|---|
| Discontinued due to AEs | —Cohort A: Triple Negative Breast C NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 27 more results—Cohort B: Ovarian Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Gastric Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort D1: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort D2: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence —Cohort E: Glioblastoma Multiforma NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort F: Biliary Tract Cancer (Le NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort G: Pancreatic Cancer (Lenva NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Experimental: Expansion 1 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination —Experimental: Expansion 2 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination —Experimental: Expansion 3 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination —Experimental: Safety Lead In NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination —300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 1.6%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination 50%2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination 66.7%1.6 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination 0%1.6 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 51.6%Cohort A: Triple Negative Breast C NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 27 more results61.3%Cohort B: Ovarian Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination 57.6%Cohort C: Gastric Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination 52.4%Cohort D1: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence · combination 40%Cohort D2: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence 29.7%Cohort E: Glioblastoma Multiforma NCT03797326 · Phase 2 · registry result, not featured evidence · combination 60.8%Cohort F: Biliary Tract Cancer (Le NCT03797326 · Phase 2 · registry result, not featured evidence · combination 47.6%Cohort G: Pancreatic Cancer (Lenva NCT03797326 · Phase 2 · registry result, not featured evidence · combination 66.7%Experimental: Expansion 1 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 60%Experimental: Expansion 2 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 35%Experimental: Expansion 3 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 16.7%Experimental: Safety Lead In NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 45%300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 51%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 40%50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 0%25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 38.2%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 35.7%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 37.5%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —1.6 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —1.6 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | hypertension 51.6% diarrhoea 45.2% hypothyroidism 45.2% NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 19 more resultshypertension 67.7% diarrhoea 61.3% decreased appetite 48.4% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 37.4% nausea 31.3% asthenia 30.3% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 56.2% diarrhoea 44.8% decreased appetite 43.8% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 56.7% diarrhoea 53.3% dysphonia 40% NCT03797326 · Phase 2 · registry result, not featured evidence hypertension 50.5% asthenia 28.7% hypothyroidism 27.7% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 56.9% diarrhoea 41.2% fatigue 39.2% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 53.4% nausea 35.9% decreased appetite 32% NCT03797326 · Phase 2 · registry result, not featured evidence · combination decreased appetite 50% alanine aminotransferase increased 33.3% diarrhea 33.3% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination anaemia 80% dizziness 80% fatigue 80% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination dizziness 45% decreased appetite 30% dyspnea 30% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination abdominal pain 66.7% blood alkaline phosphatase increased 66.7% fatigue 66.7% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 300 mg BID + 200 mg Q3W fatigue 65% nausea 55% vomiting 50% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 50% back pain 38.9% diarrhoea 38.9% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 48.4% nausea 30.1% cough 26.2% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50 mg BID + 200 mg Q3W fatigue 65% arthralgia 45% nausea 45% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 25 mg BID + 200 mg Q3W arthralgia 100% constipation 75% cough 75% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg diarrhoea 25.2% constipation 23.6% fatigue 23.6% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 75 mg aspartate aminotransferase increased 21.4% back pain 21.4% fatigue 21.4% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 50 mg fatigue 37.5% diarrhoea 25% decreased appetite 18.8% NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
Esophageal Squamous Cell Carcinoma
Shared mechanism: PD-1 · full Esophageal Squamous Cell Carcinoma pipeline
Pembrolizumab
Marketed by Merck & Co.
NCT03189719 · Phase 3 · completed
KEYNOTE-590 was a randomized, double-blind, placebo-controlled Phase 3 in 749 patients with advanced esophageal or gastroesophageal junction carcinoma. Its primary endpoints, overall and progression-free survival, are clinical outcomes and were met. The benefit was concentrated in PD-L1 CPS >=1 tumours, and the sources read give no power calculation, so the grade is moderate.
Next expected readout: December 2026 · NCT06907602 (registry estimate)
Reported efficacy
Overall Survival (OS) in Participants With Esophageal Squamous Cell Carcinoma (ESCC) Whose Tumors Are Programmed Cell Death-Ligand 1 (PD-L1) Biomarker-Positive (Combined Positive Score [CPS] ≥10) (Up to approximately 34 months); OS in Participants With ESCC (Up to approximately 34 months); OS in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10) (Up to approximately 34 months); OS in All Participants (Up to approximately 34 months); Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) As Assessed By Investigator in Participants With ESCC (Up to approximately 34 months); PFS Per RECIST 1.1 As Assessed By Investigator in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10) (Up to approximately 34 months); PFS Per RECIST 1.1 As Assessed By Investigator in All Participants (Up to approximately 34 months): Primary endpoints, overall survival and progression-free survival: pembrolizumab plus cisplatin/fluorouracil improved both vs placebo plus chemotherapy; the label restricts use to PD-L1 CPS >=1, as an exploratory CPS <1 analysis showed OS HR 0.96 (KEYTRUDA label, KEYNOTE-590). (met)
Result source: NCT03189719
Tislelizumab
Marketed by BeOne Medicines and partners
NCT03957590 · Phase 3 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 370 participants, with progression-free survival as a clinical primary endpoint. The primary comparison was not met: median progression-free survival was 29.0 versus 28.9 months, with a hazard ratio of 0.92 (95% CI 0.68–1.25; p=0.3016), so the evidence supports a well-designed but inconclusive or negative result rather than strong evidence of benefit.
Next expected readout: March 2027 · NCT07531979 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) (From randomization to the prespecified primary analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.): Progression-free Survival (PFS) (From randomization to the prespecified primary analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.): Tislelizumab + Chemoradiotherapy 29 months | Placebo + Chemoradiotherapy 28.9 months (missed)
Result source: NCT03957590
Results for Esophageal Squamous Cell Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pembrolizumab's landscape · Tislelizumab's landscape